To avoid risks resulting from discontinuation of NUC, the guideline using scoring matrix of viral antigen levels is recently summarized (Hepatol Res 2013). The aim of this study was to examine whether HBV genotype has a predictive value on the response to long-term NUC therapy in patients with CHB. Methods: We evaluated genotypes in 645 HBsAg-positive chronic HBV carriers who had a medical examination, 75 patients (genotype B: C = 47%: 53%) were administered

NUC. Of 75 patients included, mean age was 53.7 years and follow-up period was 6.1 years. The clinical and virological characteristics, such as ALT value, HBsAg (CLIA), HBV DNA (PCR), HB core-related antigen (HBcrAg, CLEIA), reported marker reflecting cccDNA levels in hepatocytes, at the time of baseline and 24 weeks, 1, 2, 5 years after that since NUC treatment initiation, were compared between subjects with genotype B and those with genotype C. buy MG-132 Both HBsAg and HBcrAg levels were scored according to the guideline Lumacaftor clinical trial by the following three groups based on the total score: low- (score 0), medium- (score 1-2), and high-risk (score 3-4). Cumulative incidence curve was estimated by the Kaplan-Meier method, the factors associated with the response to NUC therapy was evaluated by the Cox hazard model. Results: The prevalence

of ALT normalization and undetectable HBcrAg of genotype B and C at 24 weeks were 72.5% and 42% (P < .05) and 50% and 21% (P < .05), respectively. Cyclooxygenase (COX) There was no difference between both genotypes in HBV DNA seroclearance rate. Based on the scoring matrix system, the 5-year cumulative rate of archive low- and medium-risk groups (score

0-2) of genotype B and C was 29/35 (82.9%) and 12/40 (30.0%), respectively (P < .01). Multivariate analysis revealed that genotype B was the most predictive factor associated with archive score 0-2 (HR, 2.96; 95%CI, 1.14-7.70; P =.03), compared with age at the start of NUC treatment (HR, 1.04; 95%CI, 1.00-1.08; P =.04) and pretreatment ALT (HR, 1.0; 95%CI, 0.99-1.00). Conclusions: In Japanese CHB patients, genotype B shows a better virological response to NUC therapy than genotype C. This suggests that HBV genotype is a useful indicator to predict response to NUC therapy and to efficiently identify the patients at risk for relapsing of hepatitis resulting from discontinuation of NUC. Disclosures; The following people have nothing to disclose: Hisayoshi Watanabe, Chikako Sato, Kei Mizuno, Tomohiro Katsumi, Kyoko Tomita, Kazuo Okumoto, Yuko Nishise, Takafumi Saito, Sumio Kawata Background: Entecavir has demonstrated superior histologic, virologic, and biochemical benefits for chronic hepatitis B worldwide. Still, its long-term clinical outcome is not well established in Korean clinical area, and also in subjects who stopped the treatment .